Foghorn Therapeutics develops a new class of precision medicines that correct abnormal gene expression by targeting dependencies in the chromatin regulatory system. Its Gene Traffic Control platform enables systematic identification and validation of therapeutic targets, with an initial focus on oncology indications such as non-small cell lung cancer and lymphomas. The company maintains a collaboration with Eli Lilly for one of its programs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 7.6 | — | -17.9 | — |
| Q3 2025 | 8.2 | — | -15.8 | — |
| Q4 2025 | 9.3 | — | -21.7 | — |
| Q1 2026 | 3.3 | — | -19.9 | — |
| Q2 2026 | 16.1 | 112.7% | -7.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: EGH Acquisition Corp. (EGHA), Greenwich LifeSciences, Inc. (GLSI), Cartesian Therapeutics, Inc. (RNAC), Lyell Immunopharma, Inc. (LYEL), TON Strategy Co (TONX), Invivyd, Inc. (IVVD)